The trial will evaluate Sym004 in patients suffering from recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
The Phase 2 trial aims at progression free survival at 24 weeks.
Symphogen CEO Kirsten Drejer said they are very excited about advancing this compound into clinical evaluation for treatment of SCCHN as well as mCRC in patients who have failed anti-EGFR antibody based therapy.